Hydrochloric Acid
Aqua Solutions Hydrochloric Acid (1:1) 50% v/v Solution ASTM D1125-14 (4L)
Hydrochloric Acid (1:1) 50% v/v Solution ASTM D1125-14 (4L)
Aqua Solutions Hydrochloric Acid (1:1) 50% v/v Solution ASTM D1125-14 (4L)
Hydrochloric Acid (1:1) 50% v/v Solution ASTM D1125-14 (4L)
Aqua Solutions Hydrochloric Acid (1:1) 50% v/v Solution ASTM D1125-14 (4L)
Hydrochloric Acid (1:1) 50% v/v Solution ASTM D1125-14 (4L)
Medchemexpress LLC ARD-69 | 5MG
ARD-69 is a PROTAC degrader based on the E3 ubiquitin ligase VHL and targeting the androgen receptor which can induce androgen receptor (AR) protein degradation in AR-positive prostate cancer cells ARD-69 inhibits AR-regulated gene expression binds to the AR ligand binding domain at one end and binds to VHL at the other end prompting AR to be recruited to the E3 ubiquitin ligase complex triggering proteasome degradation thereby inhibiting AR signaling pathways and downstream gene expression (such as PSA TMPRSS2) ARD-69 can be used to study the treatment of castration-resistant prostate cancer (mCRPC)[1][2][3] br/ ARD-69 is composed of a target protein ligand (pink part) AR antagonist 14 (HY-172624) a PROTAC linker (black part) tert-Butyl 4-ethynyl-[1 4 -bipiperidine]-1 -carboxylate (HY-W442074) and a VHL-type E3 ubiquitinase ligand (blue part) VH 101 acid (HY-47070) among them the VHL ligand and the linker can form a conjugate VH 101-amide-piperidine-Pip-alkyn
Medchemexpress LLC ARD-69 1mg | 2316837-10-0 | 1 MG
ARD-69 is a PROTAC degrader based on the E3 ubiquitin ligase VHL and targeting the androgen receptor which can induce androgen receptor (AR) protein degradation in AR-positive prostate cancer cells ARD-69 inhibits AR-regulated gene expression binds to the AR ligand binding domain at one end and binds to VHL at the other end prompting AR to be recruited to the E3 ubiquitin ligase complex triggering proteasome degradation thereby inhibiting AR signaling pathways and downstream gene expression (such as PSA TMPRSS2) ARD-69 can be used to study the treatment of castration-resistant prostate cancer (mCRPC)[1][2][3] br/ ARD-69 is composed of a target protein ligand (pink part) AR antagonist 14 (HY-172624) a PROTAC linker (black part) tert-Butyl 4-ethynyl-[1 4 -bipiperidine]-1 -carboxylate (HY-W442074) and a VHL-type E3 ubiquitinase ligand (blue part) VH 101 acid (HY-47070) among them the VHL ligand and the linker can form a conjugate VH 101-amide-piperidine-Pip-alkyn